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Liga and collaborators reported on low doses of donor
lymphocytes given after Tcelledepleted transplants for acute
leukemia [1]. Patients received lymphocytes if they had
evidence of mixed chimerism after transplant or if disease
was deemed to be at high risk of relapse. Ultimately, 15 of 56
patients undergoing transplantation received prophylactic
donor lymphocytes, which induced full donor chimerism in
75%of the cases.Despite amedian infused cell doseof only2
106 CD3/kg (given at a median of 162 days after transplant),
the donor lymphocyte infusion (DLI)-related mortality was
estimated at 27% (4 graft-versus-host disease [GVHD]-related
deaths). No recurrences were seen among the remaining 11
recipients of prophylactic lymphocytes.
This study illustrates the complexities, successes, and
limitations of our current understanding (or lack thereof) of
post-transplantation relapse biology, prevention, and treat-
ment. Relapse occurs in approximately 40% of patients and
remains the most common cause of death after trans-
plantation; the prognosis of patients with most hematologic
malignancies that relapse after allogeneic transplants isunfortunately very guarded [2]. DLIs have been used most
frequently in the context of relapse but with varied results
and signiﬁcant treatment-related mortality, due to GVHD
and infections. Depleting the graft of alloreactive T cells
(in vivo or ex vivo) has led to remarkably low GVHD rates,
with varying results in terms of relapse, infections, compli-
cations, and primary disease relapse. T cell “add back,” as
proposed by Liga et al., may, to some extent, defy the original
proposition of graft T cell depletion, in that it is often
complicated by the same problems (ie, GVHD) the T cell
depletion intended to avoid. Delaying the infusion does
decrease the likelihood of GVHD but, as demonstrated here,
does not abolish the risk. The strategy of delaying the DLI
used to prevent relapse also is not devoid of risks: A signif-
icant fraction of acute leukemia relapses after allogeneic
transplants occurs during the ﬁrst 6 months. In the report of
Liga et al. patients that received the prophylactic lympho-
cytes, however, did not relapse.
Review of the literature of planned DLIs illustrates the
variability in approaches. Median cumulative cell doses
ranges from 0.2  106 to 70  106 T cells/kg, with a highly
variable schedule of infusions [2]. In addition to prophylactic
DLIs, multiple methods have been proposed over the years to
minimize the likelihood of recurrence, ranging from
intensiﬁed preparative regimens to newer cell therapy or
vaccination approaches designed to increase the graft-
versus-leukemia effect without GVHD [3-6]. When
analyzed disregarding single-center reports, relapse rates for
high-risk patients have not changed much since Dr. Thomas’
initial publications in the 1970s and 1980s, unfortunately.
The same considerations of lack of consensus and absence of
uniformly effective treatments characterize the scenario of
relapse treatment as well.
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ously complex and not available in 2012. We need more
collaboration between basic scientists, translational
researchers, and cliniciansdand we need collaborative
clinical trials that would stem from this interaction.
The biology, prevention, and treatment of relapse after
transplantation were the subjects of the second National
Cancer Instituteesponsored symposium, which took place in
Bethesda, Maryland, November 5 and 6, 2012. The major
consensus obtained in thismeetingwas that the ﬁeld will not
advance unless more intense partnerships among members
of our community are achieved. Investigators had the
opportunity to review topics related to the biology of relapse
and to propose studies and discuss feasibility of potential
collective endeavors. The Biology of Relapse Committee
proposed a multicenter, standardized sample-collection
protocol that would allow collection of donor samples,
germline and tumor cells, and, hopefully, the prospective
accrual of pre- and postrelapse samples. Possible ways to
increase the graft-versus-leukemia effect by combining
treatment modalities (such as hypomethylating agents,
which may increase expression of leukemia-associated
antigens, and PR-1 peptide vaccination, or cytokines, such
as interleukin-7, and tumor vaccination) were favored.
Summaries and manuscripts derived from this symposium
will become available in upcoming issues of Biology of Blood
and Marrow Transplantation.
Liga and collaborators have addressed amajor issue in our
ﬁeld and should be commended for their effort. It is unlikely,
however, that any single intervention will dramatically
change the problem of relapse after allogeneic transplant; it
is likely to continue to be a stepwise process [7]. Rather, the
word “collaboration,” used liberally in this commentary,should be our main agenda if we are to help more and more
of our patients.ACKNOWLEDGMENT
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